ERBB2 and neoplasm: There is no evidence to support staging HER2‐positive or triple‐negative high‐grade breast carcinomas that lack a peripheral MEC layer as in situ disease based on circumscription or papillary architecture, as these tumour phenotypes typically reflect biologically aggressive invasive disease (Figure 4C) and warrant adjuvant therapy.